The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Eric L. Simpson(Oregon Health & Science University), Amy S. Paller(Northwestern University), Steven R. Feldman(Wake Forest University), Jonathan I. Silverberg(George Washington University), Ariane Dubost-Brama(Galderma (France)), Henrique D. Teixeira(AbbVie (United States)), Thomas Bieber(CK-CARE), Kenji Kabashima(Kyoto University), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Anne Parneix(Novartis (United States)), Y. Joubert(Novartis (Switzerland)), Robert Bissonnette(Innovaderm (Canada)), Gil Yosipovitch(University of Miami), Paul Klekotka(Eli Lilly (United States)), M. Milutinovic(Novartis (Switzerland)), Lotus Mallbris(Karolinska Institutet), Amy M. DeLozier(Eli Lilly (United States)), Marieke M.B. Seyger(Radboud University Nijmegen), Fabio P. Nunes(Eli Lilly (United States)), Steve Frey(GlaxoSmithKline (United States)), Brett King(Yale University), Lawrence F. Eichenfield(University of California San Diego), Alan Menter(Baylor Medical Center at Garland), Yves Dutronc(Albert Einstein College of Medicine), Lisa A. Beck(University of Rochester Medicine), C. Paul(Université Fédérale de Toulouse Midi-Pyrénées), Elaine C. Siegfried(Saint Louis University), Georg Stingl(Medical University of Vienna), Chen-Yen Lin(Eli Lilly (United States)), Luna Sun(Eli Lilly (United States)), John Armstrong(Galderma (France)), Peter van de Kerkhof(Radboud University Nijmegen), Brian J. Nickoloff(United BioSource Corporation (United Kingdom)), Jonathan Janes(Eli Lilly (United States)), Kristian Reich(Dermatologikum Hamburg), Philippe Martel(Galderma (France)), Rajeev Chavda(Galderma (Switzerland))
Cited by 181
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k